Halozyme Therapeutics, Inc.
HALO· Nasdaq
HALOHalozyme Therapeutics, Inc.
Filed Nov 8, 2012 · 10-Q · 39 days after period end · 0001193125-12-460700
| Metric | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|
| Revenue | $5.33M | $22.94M | $3.40M |
| Net Income | -$20.01M | $5.17M | -$12.41M |
| EPS Diluted | -$0.18 | $0.05 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
ended Sep 30, 2012 · filed Nov 8, 2012 · 39 d after period end
